Journey Medical Corp (DERM) research

Journey Medical Corp
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$7.25
As of

Journey Medical Corp (DERM): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.

As of . Source: SEC EDGAR filings for DERM. Method and limitations.

SHARE THIS CARD

Share the DERM intelligence card

A branded snapshot of DERM: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion DERM intelligence card preview
Post to X
LIVE TERMINAL

See DERM live in the terminal

Track DERM's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live DERM terminal, free

Active signals for DERM

FREE, NO ACCOUNT

Every signal on DERM, as it fires

You are seeing 5 of 10 signals recorded on DERM since 2026-05-29.

The five above landed across 2 days. The other 5 were recorded on 1 other days. 7 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in DERM (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 48115J109 · 2026Q2$1.6M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 48115J109 · 2026Q2$779K0.00%,
CITADEL ADVISORS LLCCUSIP 48115J109 · 2026Q2$582K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, DERM

DERM mentioned in Kresmion daily briefs

DERM against its peers

DERM's operating margin of -13.3% ranks in the 32nd percentile of 16 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.

MetricDERMPeer medianPercentilen
Revenue FY61.2M USD180M USD3415
Gross marginn/a43.5%n/a13
Operating margin-13.3%-5.3%3216
Net margin-18.7%-24.9%6216
Return on equity-35.9%-20.7%4212

Peers (18): TSNDF, CRDL, AKBA, ELTP, CRLBF, ADCT, GRUSF, AAWH, BGM, CGC, CPIX, VRNO, NIKA, CWBHF, TKNO, JUSHF, KMDA, EOLS. Left out: LFCR (no annual filing), PHBI (period gap), OGI (period gap), ASRT (no annual filing), BORAY (no annual filing), CTOR (no annual filing), INCR (period gap). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (DERM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more DERM signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to DERMand get the insider, 13F, options, and confluence read in one view.

Open the live DERM terminal, free